ICI combination rechallenge does not improve outcomes in advanced renal cell carcinoma - Urology Times
ICI 組合再挑戰對於晚期腎細胞癌的結果沒有改善。

Impact of Non-Dialysis-Requiring Acute Kidney Injury on Survival Outcomes in Non-critically Ill Hospitalized Medical Patients in a Resource-Limited Setting: A Retrospective Cohort Study - Cureus
在資源有限的環境中，非重症住院醫療病人中，非透析需求的急性腎損傷對生存結果的影響：一項回顧性隊列研究

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer - News-Medical.Net
試驗發現將 nivolumab 加入 tivozanib 對於晚期腎癌沒有益處

NKT-2152: Promising New HIF-2 Alpha Inhibitor for Advanced Renal Cell Carcinoma - Eric Jonasch - UroToday
NKT-2152：對於晚期腎細胞癌有前景的新型 HIF-2 Alpha 抑制劑

Polygenic scores and their applications in kidney disease - Nature.com
多基因得分及其在腎臟疾病中的應用

How the CVAC System compares with URS for treating kidney stones - Urology Times
CVAC 系統與 URS 在治療腎結石方面的比較

Extreme heat due to climate crisis puts people at greater risk of kidney disease - The Guardian US
氣候危機造成的極端高溫使人們面臨更高的腎臟疾病風險。

Belzutifan is associated with PFS and ORR gains in advanced kidney cancer - Urology Times
Belzutifan 與晚期腎癌的無進展生存期 (PFS) 和整體響應率 (ORR) 的提升有關。

Decision factors for pediatric kidney replacement therapies may differ from guidelines - Healio
兒童腎臟替代療法的決策因素可能與指導方針不同。

Association between the lipid accumulation product and chronic kidney disease among adults in the United States - Nature.com
美國成年人中脂質積累產物與慢性腎病的關聯

Repeat immune checkpoint inhibitor therapy not rec | Newswise - Newswise
重複免疫檢查點抑制劑療法不推薦 | Newswise

Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function - Medscape
Semaglutide 減少心血管事件（MACE）、死亡率，適用於有心血管疾病（CVD）、超重/肥胖及腎功能受損的參與者。

Semaglutide Reduces MACE, Death in Impaired Kidney Function - Medscape
Semaglutide 減少腎功能受損患者的 MACE 和死亡率

Potential ADPKD Rapid Progression Marker Identified - Renal and Urology News
潛在的ADPKD快速進展標記已被識別

TiNivo-2 Trial Results: Tivozanib in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri - UroToday
TiNivo-2 試驗結果：Tivozanib 在晚期腎細胞癌治療中的效果

Warming climate putting people at greater risk of kidney disease – study - The Guardian US
氣候變暖使人們面臨更高的腎臟疾病風險 – 研究

ESMO: Despite positive trial, Merck's Welireg still comes up short in overall survival - FiercePharma
ESMO：儘管試驗結果良好，Merck 的 Welireg 在整體生存率上仍然不夠理想。

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function - News-Medical.Net
研究突顯了semaglutide對於腎功能受損的超重成人的心血管益處。

Oban renal patients travelling five hours for treatment - BBC.com
奧班的腎臟病患者為了治療而旅行五個小時

Turning Personal Loss into Personal Connections: A Nurse’s Journey Through Kidney Care and Heartbreak - DailyNurse
將個人的失落轉化為個人的連結：一位護士在腎臟護理與心碎中的旅程